Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

New collaboration aims to prevent life-threatening adverse reactions to medications

The University of Arizona College of Medicine - Phoenix and Banner Health are collaborating to prevent life-threatening adverse reactions to medications.

27 Feb 2019

New PET/CT tracer shows high detection rate for diagnosis of acute venous thromboembolism

A first-in-human study featured in the February issue of The Journal of Nuclear Medicine reports that the novel positron emission tomography/computed tomography tracer 18F-GP1 showed excellent image quality and a high detection rate for the diagnosis of acute venous thromboembolism.

18 Feb 2019

Scientists show treatment success in minimally invasive heart valve procedure

Scientists at the Center for Cardiology of the Mainz University Medical Center have examined the success of more than 13,575 minimally invasive procedures on the mitral valve in the largest study of their kind to date.

5 Feb 2019

New study adds evidence to efficacy and safety of low-dose vaginal estrogen

Despite its proven effectiveness in treating the genital symptoms of menopause, low-dose vaginal estrogen therapy remains underused largely because of misperceptions regarding its safety.

19 Dec 2018

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.

4 Dec 2018

New clinical practice guidelines for managing venous thromboembolism released

Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.

28 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

New standard of care aims to prevent deaths caused by largely preventable blood clots

A new nationally agreed standard of care released today (Thursday) aims to reduce the tens of thousands of Australian lives put at risk each year by largely preventable blood clots, which kill four times more people than road accidents.

12 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Patients with venous thromboembolism carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE concluded that the risk of recurrence is substantial.

25 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Using clinical quality registers to compare institutions or physicians may be misleading

Many clinical quality registries have been established during the 2000s, particularly in North America where such registers are used as a criterion for health care funding.

28 Aug 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

Researchers develop new model for predicting cancer-associated venous thrombosis

In collaboration with international partners, a study group from the Medical University of Vienna has developed a new model for predicting cancer-associated venous thrombosis/pulmonary embolism.

11 Jul 2018

Study using i2b2 could help standardize artificial coma treatment for RSE patients

Status epilepticus, a dangerous condition in which epileptic seizures follow one another for a duration of five or more minutes without the victim's regaining consciousness between them, is the second most common neurological emergency in the United States, with a recorded maximum of around 150,000-plus cases per year.

30 Jun 2018

Pulmonary Embolism News and Research

Further Reading

New collaboration aims to prevent life-threatening adverse reactions to medications

New PET/CT tracer shows high detection rate for diagnosis of acute venous thromboembolism

Scientists show treatment success in minimally invasive heart valve procedure

New study adds evidence to efficacy and safety of low-dose vaginal estrogen

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

New clinical practice guidelines for managing venous thromboembolism released

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

New standard of care aims to prevent deaths caused by largely preventable blood clots

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Using clinical quality registers to compare institutions or physicians may be misleading

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

Researchers develop new model for predicting cancer-associated venous thrombosis

Study using i2b2 could help standardize artificial coma treatment for RSE patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News